Global Agomelatine Market 2024-2030
  • CHOOSE LICENCE TYPE
Consulting Services
    How will you benefit from our consulting services ?

Global Agomelatine Market 2024-2030

Last Updated:  Apr 25, 2025 | Study Period: 2024-2030

AGOMELATINE MARKET

 

INTRODUCTIONAGOMELATINE MARKET

 Atypical antidepressants like agomelatine, which is also sold under the names Valdoxan and Thymanax, are most commonly used to treat major depressive disorder and generalized anxiety disorder. According to one review, it is just as effective as other antidepressants, with similar overall discontinuation rates and fewer withdrawals due to side effects.

 

It was also found to be as effective as many other antidepressants in another review.

 

Weight gain, fatigue, liver issues, nausea, headaches, and anxiety are all common side effects. Continuous blood tests are recommended due to potential liver issues. Its utilization isn't suggested in individuals with dementia or beyond 75 years old. There is conditional proof that it might have less secondary effects than a few different antidepressants.

 

Agomelatine works by activating melatonin receptors and blocking some serotonin receptors. It was approved for medical use in Australia and Europe. However, its use in the United States is not approved, so efforts to get approval were stopped. An antidepressant used to treat depression, Servier Agomelatine was developed by the pharmaceutical company.

 

The mind is generally great at ensuring we have enough of the synthetics we want to appropriately work. However, a number of brain chemicals can be altered by depression.

 

AGOMELATINE MARKETSIZE AND FORECAST

 

Infographic: Agomelatine Market, Agomelatine Market Size, Agomelatine Market Trends, Agomelatine Market Forecast, Agomelatine Market Risks, Agomelatine Market Report, Agomelatine Market Share

 

TheGlobal agomelatine marketaccounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

 

AGOMELATINE MARKETRECENT DEVELOPMENTS

Given that affective disorders are characterised by abnormal circadian rhythms, the development of antidepressants with melatonin agonist and 5-HT2C antagonist properties may be promising (Germain & Kupfer,). Agomelatine has been shown to be effective in treating major depressive disorders in a number of clinical trials (Kennedy & Emsley, 2006; De Bodinat et al., 0.

 

It acts as an agonist at melatonergic receptors and an antagonist at 5-HT2C receptors., Lôo et al.; by Olié and Kasper). One way agomelatine is effective in treating depression is by resynchronizing circadian rhythms, which may be due to this novel receptor profile (for a review, see Gorwood, Kasper et al ).

 

It is interesting to note that agomelatine also exhibits robust antidepressant and anxiety-reducing properties in a variety of animal models.

 

A new mouse model of a depressive or anxious state induced in rodents by prolonged exposure to exogenous corticosterone (4-pregnen-11b-diol-3,20-dione 21-hemisuccinate) was recently created.

 

In this model, we demonstrated that chronic treatment with fluoxetine was effective in reversing the flattened circadian rhythm but not in reversing the inhibition of hippocampal neurogenesis or behavioural dysfunction caused by chronic corticosterone (David et al.,).

 

They first evaluated agomelatine's antidepressant/anxiety-like activity in the chronic corticosterone animal model of a depressive/anxiety-like state because it has a different mechanism of action than the antidepressants that are currently available.

 

In various paradigms like the open-field paradigm (OF), novelty suppressed feeding (NSF), the splash test (ST), the forced swim test (FST), and the coat state, we compared the behavioural effects of chronic agomelatine (10 or 40 mg/kg.d) or fluoxetine .

 

They also investigated whether agomelatine reversed the flattened circadian rhythm in chronic corticosterone-treated mice, given that mood disorders are often associated with circadian rhythm desynchronization.

 

AGOMELATINE MARKETCOMPANY PROFILE

 

THISAGOMELATINE MARKETREPORT WILL ANSWER FOLLOWING QUESTIONS

 

  1. How many agomelatine are manufactured per annum globally? Who are the sub-component suppliers in different regions?
  2. Cost breakup of a Global agomelatine and key vendor selection criteria
  3. Where is the agomelatine manufactured? What is the average margin per unit?
  4. Market share of Global agomelatine market manufacturers and their upcoming products
  5. Cost advantage for OEMs who manufacture Global agomelatine in-house
  6. key predictions for next 5 years in Global agomelatine market
  7. Average B-2-B agomelatine market price in all segments
  8. Latest trends in agomelatine market, by every market segment
  9. The market size (both volume and value) of the agomelatine market in 2024-2030 and every year in between?
  10. Production breakup of agomelatine market, by suppliers and their OEM relationship

 

Sl noTopic
1Market Segmentation
2Scope of the report
3Abbreviations
4Research Methodology
5Executive Summary
6Introduction
7Insights from Industry stakeholders
8Cost breakdown of Product by sub-components and average profit margin
9Disruptive innovation in the Industry
10Technology trends in the Industry
11Consumer trends in the industry
12Recent Production Milestones
13Component Manufacturing in US, EU and China
14COVID-19 impact on overall market
15COVID-19 impact on Production of components
16COVID-19 impact on Point of sale
17Market Segmentation, Dynamics and Forecast by Geography, 2024-2030
18Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030
19Market Segmentation, Dynamics and Forecast by Application, 2024-2030
20Market Segmentation, Dynamics and Forecast by End use, 2024-2030
21Product installation rate by OEM, 2023
22Incline/Decline in Average B-2-B selling price in past 5 years
23Competition from substitute products
24Gross margin and average profitability of suppliers
25New product development in past 12 months
26M&A in past 12 months
27Growth strategy of leading players
28Market share of vendors, 2023
29Company Profiles
30Unmet needs and opportunity for new suppliers
31Conclusion
32Appendix